Colorectal Cancer Clinical Trials in Denver, Colorado

9 studies are recruiting for colorectal cancer in Denver, Colorado right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

   The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, toler…

   Stage

   Phase 1

   Ages

   12 and older

   Site

   Rocky Mountain Cancer Center, Denver, Colorado

   Locations

   77 in total

   Run by

   PMV Pharmaceuticals, Inc

   See if you can join NCT04585750 on ClinicalTrials.gov

2. A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer

   This is a study to evaluate the safety and preliminary anti-tumor activity of STRO-004 in adults with metastatic cancer. This study includes 3 parts: * Part 1A is a dose escalation study of STRO-004 monotherapy in selected tumor types known to commonly express Tissue Factor (TF). * Part 1B is a coh…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   SCRI Denver, Denver, Colorado

   Locations

   9 in total

   Run by

   Sutro Biopharma, Inc.

   See if you can join NCT07227168 on ClinicalTrials.gov

3. MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

   The main purpose of this study is to assess safety \& tolerability and antitumor activity of LY3962673 as monotherapy and in combination with other chemotherapy agents in participants with KRAS G12D-mutant advanced solid tumor types. The study is expected to last approximately 5 years.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Sarah Cannon Research Institute at HealthOne, Denver, Colorado

   Locations

   52 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06586515 on ClinicalTrials.gov

4. A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors

   This is an open-label, multi-center, phase I study to evaluate the safety, tolerability, efficacy, and pharmacokinetics of MRG007 (ARR-217) in patients with unresectable locally advanced or metastatic solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Sarah Cannon Research Institute, Denver, Colorado

   Locations

   21 in total

   Run by

   ArriVent BioPharma, Inc.

   See if you can join NCT07066657 on ClinicalTrials.gov

5. A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types

   This is a Phase 1a/1b, open-label, multicenter dose escalation and dose expansion clinical study to evaluate the safety, PK, immunogenicity and preliminary efficacy of IDE034 in participants with locally advanced/metastatic solid tumor types that express B7-H3 and PTK7.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Sarah Cannon Research Institute at HealthONE, Denver, Colorado

   Locations

   15 in total

   Run by

   IDEAYA Biosciences

   See if you can join NCT07503808 on ClinicalTrials.gov

6. CT-95 in Advanced Cancers Associated With Mesothelin Expression

   This is a Phase 1a/1b, first-in-human (FIH), open-label, multi-center dose escalation and expansion study of the safety, pharmacokinetics (PK), pharmacodynamics, and antitumor activity of single-agent CT-95 in subjects with advanced (recurrent, unresectable, or metastatic) cancers associated with M…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Context Investigational Site, Denver, Colorado

   Locations

   9 in total

   Run by

   Context Therapeutics Inc.

   See if you can join NCT06756035 on ClinicalTrials.gov

7. A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL)

   This is an open-label multicenter, single-arm Phase II study of Fruquintinib in combination with FOLFIRI (leucovorin calcium (folinic acid), fluorouracil, and irinotecan) in participants with metastatic colorectal cancer (mCRC). The main goals of this study are to: * Evaluate the efficacy of the co…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Rocky Mountain Cancer Center - Primary, Denver, Colorado

   Locations

   14 in total

   Run by

   SCRI Development Innovations, LLC

   See if you can join NCT07011576 on ClinicalTrials.gov

8. Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

   This is a Phase 1/2, multi-center, open-label basket study designed to evaluate the safety and anti-tumor activity of IDE196 in patients with solid tumors harboring GNAQ or GNA11 (GNAQ/11) mutations or PRKC fusions, including metastatic uveal melanoma (MUM), cutaneous melanoma, colorectal cancer, a…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   SCRI - Denver, Denver, Colorado

   Locations

   15 in total

   Run by

   IDEAYA Biosciences

   See if you can join NCT03947385 on ClinicalTrials.gov

9. Exogenous and Endogenous Risk Factors for Early-onset Colorectal Cancer

   An increase in early-onset colorectal cancers (eoCRC), defined as a CRC before 50 years, is confirmed globally. CRC pathogenesis has been associated with several risk factors (family history, germline pathogenic variants, obesity, alcohol, physical activity, red meat, and a Western diet). Design: a…

   Stage

   Not phased

   Ages

   18 to 49

   Site

   Department of Medicine-Gastroenterology, Denver Veterans Affairs Medical Center, University of Colorado Hospital, Denver, Colorado

   Locations

   8 in total

   Run by

   San Raffaele University

   See if you can join NCT05732623 on ClinicalTrials.gov